Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Smoking Clinical Trial

Official title:

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02800928
• Other study ID #: 1602017291
• Secondary ID: P50DA033945
• Status: Completed
• Phase: Phase 2
• Start date: June 30, 2016
• Est. completion date: January 2, 2018

Study information

• Verified date: July 2019
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Stress-precipitated Smoking Behavior.

Description:

The study will be performed in subjects who are heavy cigarette smokers currently not seeking treatment for tobacco use disorder.

The study is a crossover design study (within-subject analysis), which allows for subjects to be their own control.

Each period of the crossover consists of a 7-day out-patient treatment period followed by a single out-patient testing day on Day 8. Subjects will participate in a laboratory session following the McKee Stress-Smoking Lapse Test. Upon completion, subjects will undergo a 7 day washout period followed by the second period of the crossover design and a 7-day follow-up visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 2, 2018
• Est. primary completion date: January 2, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria

1. Provides written informed consent and agrees to complete required clinic visits

2. Male or female 21 to 60 years of age inclusive

3. Body mass index (BMI) 18.5 to 40 kg/m2 inclusive

4. Smokes at least 10 cigarettes per day on average for the past 6 months

5. Fagerstrom score =3 at screening

6. Currently not seeking smoking cessation therapy

7. Urine dip test for cotinine concentration >150 ng/mL

8. In otherwise good general health without any unstable medical conditions (as determined by medical history, medication history, physical examination, 10- or 12 lead ECG, vital signs, and clinical laboratory testing)

9. Able to read, write, and speak English

10. Females must be either:

1. Post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile -or-

2. Women of childbearing potential (WOCBP) must meet the criteria below:

i. Uses an acceptable double-barrier method of contraception as determined by the Investigator -and- ii. Is not lactating, has a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test prior to dosing on Days 1 and 8 of each treatment period.

11. Male subjects must agree to use a condom if partner is of childbearing potential

Exclusion Criteria

1. Have used tobacco or other nicotine containing products other than cigarettes (e.g., nicotine patches, pipe, cigars, snuff, chewing tobacco or e-cigarettes) within the past 30 days

2. Any substance use disorder other than nicotine or caffeine as assessed by the Structured Clinical Interview-IV Axis I Disorders (SCID) for Diagnostic and Statistical Manual of Mental Disorders (DSM)

3. Current neurological conditions that interfere with study conduct, assessment or treatment in any significant fashion

4. Any lifetime history of bipolar I, II; schizophrenia or any other psychotic disorders; personality disorders, impulse control disorders as assessed by the SCID-IV

5. Current psychiatric conditions that interfere with study conduct, assessment, or treatment in any significant fashion, such as major depressive disorder (MDD), eating disorders, post-traumatic stress disorder, etc. We will screen for worsening of symptoms of depression and/or suicidality at each medication appointment and lab sessions by having participants complete the Beck Depression Inventory (BDI) and the Columbia-Suicide Severity Rating Scale (C-SSRS). If there is a worsening of symptoms of depression and/or suicidality, the participants will speak a licensed psychologist for evaluation.

6. Recent active or past history of gastric disease such as peptic ulcer disease, gastritis, upper gastrointestinal bleeding, or any gastrointestinal malignancy or precancerous condition

7. Active, comorbid disease that might limit the ability of the subject to participate in the study as determined by the Study MD (i.e., poorly controlled diabetes mellitus, congestive heart failure, etc.)

8. Clinically significant clinical laboratory test taken during screening

9. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =2 times the upper limit of normal (ULN)

10. Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C positive as determined by serology testing at Screening

11. Positive ethanol breath test at screening or prior to dosing on Days 1 and 8 of each treatment period

12. Positive urine drug test at screening or and/or prior to dosing on Days 1 and 8 of each treatment period except for cannabis

13. History of severe allergies or multiple adverse drug reactions

14. Known hypersensitivity to CERC-501

15. Current use of a proton pump inhibitor or histamine 2 blocker

16. Use of any investigational medication within 2 months prior to the start of this study or scheduled to receive an investigational drug other than the study drug during the course of this study

17. Current use of any psychoactive medications including: antipsychotics, benzodiazepines, mood stabilizers, selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) or other antidepressants mood stabilizers

Related Conditions & MeSH terms

• Smoking

Intervention

Drug:
• CERC-501
CERC-501
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Yale University School of Medicine	New Haven	Connecticut

Sponsors (4)

Lead Sponsor	Collaborator
Yale University	Janssen Pharmaceuticals, National Institute on Drug Abuse (NIDA), Office of Research on Women's Health (ORWH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Latency	Latency (in minutes and seconds) to time of first cigarette smoking during the delay period	50 min
Primary	Number of Cigarettes Smoked	Number of cigarettes smoked during the self administration period	60 min